FDA fast-tracks Snipr Biome's primary candidate

Snipr Biome’s CRISPR treatment of blood infections in cancer patients has been granted special status by the US Food and Drug Administration.

Photo: Snipr Biome/PR

Just two weeks after the FDA approved the development plans for Snipr Biome’s candidate, SNIPR001, the company now reveals it has been awarded fast-track status.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs